As previously reported, on December 12, 2017, the Ontario Legislature passed the Strengthening Quality and Accountability for Patients Act, 2017, which enacts or amends 10 statutes including the Health Sector Payment Transparency Act, 2017 (Transparency Act). When in force, the Transparency Act will require disclosure of financial relationships between pharmaceutical or medical device manufacturers (among other “payors”) and health care professionals (among other “recipients”). On February 21, 2018, the Ontario Ministry of Health and Long-Term Care published for consultation proposed regulations under the Transparency Act. The proposed regulations specify: what constitutes a “transfer of value” that must be reported; who qualifies as an “intermediary” or a “recipient” of a “transfer of value”; additional categories of “payors”; what thresholds and exemptions exist to the reporting requirements; the manner and frequency of reporting; and the process for correcting posted information. The consultation period ends April 6, 2018.
Related Publications & Articles
-
Health Canada and the Competition Bureau commit to information sharing to combat false, misleading or deceptive health claims
On March 7, 2024, Health Canada published a Memorandum of Understanding (MOU) with the Competition Bureau (together, Participants) to advance their mutual interests and develop a framework of cooperat...Read More -
Update on biosimilars in Canada – March 2024
In this article, we provide a further update on developments regarding biosimilars in Canada (approvals, pending submissions, litigation, regulatory, and market access).Read More -
Generic Submissions Under Review list will identify generic filers
On February 23, 2024, Health Canada announced that it will expand the information available on the Generic Submissions Under Review (GSUR) list.Read More